Senores Pharmaceuticals, a leading drug maker, concluded its IPO on December 24, 2024, with an overwhelming subscription rate of 93.41 times. The basis of allotment is set to be finalized on Thursday, December 26, 2024, with bidders receiving updates on fund debits or IPO mandate revocations by Friday, December 27, 2024.
Key Details of the IPO
Advertisement
- Price Band: ₹372 – ₹391 per share
- Lot Size: 38 shares
- IPO Size: ₹582.11 crore
- Fresh Issue: ₹500 crore
- Offer-for-Sale (OFS): 21,00,000 equity shares
Subscription Status
The IPO received a robust response across investor categories:
- Qualified Institutional Buyers (QIBs): 94.66 times
- Non-Institutional Investors (NIIs): 96.11 times
- Retail Investors: 89.23 times
- Employees: 19.92 times
Grey Market Premium (GMP)
As of the latest updates, Senores Pharmaceuticals commands a GMP of ₹284, indicating a 72.63% premium over the upper price band of ₹391. The expected listing price is ₹675 per share, reflecting strong demand in the unofficial market.
Listing Timeline
- Allotment Finalization: December 26, 2024
- Refunds/Unblocking of Funds: December 27, 2024
- Shares Credit to Demat Accounts: December 29, 2024
- Listing Date: Expected early next week
Content retrieved from: https://www.businessupturn.com/finance/ipo/senores-pharmaceuticals-ipo-check-latest-gmp-ahead-of-listing/.
